Net clinical benefit of edoxaban for stroke, mortality, and bleeding risk modeling projections for a European population

JACC: Clinical Electrophysiology

Volumn 2, Issue 1, 2016, Pages 47-54

  Blann, Andrew D ^a   Pisters, Ron ^b   Lip, Gregory Y H ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c AALBORG UNIVERSITY   (Denmark)

Author keywords

atrial fibrillation; edoxaban; net clinical benefit; oral anticoagulation; warfarin

Indexed keywords

EDOXABAN; WARFARIN;

AGED; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHADS2 SCORE; DRUG EFFICACY; DRUG SAFETY; EUROPEAN; FEMALE; HIGH RISK POPULATION; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK REDUCTION; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84959010730     PISSN: 2405500X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacep.2015.09.015     Document Type: Article

References (29)

1. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation Chest 137 2010 263 272
2. D. Keeling, T. Baglin, C. Tait, et al. for the British Committee for Standards in Haematology Guidelines on oral anticoagulation with warfarin, fourth edition Br J Haematol 154 2011 311 324
3. D.A. Fitzmaurice, A.D. Blann, and G.Y. Lip Bleeding risks of antithrombotic therapy BMJ 325 2002 828 831
4. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
5. D.E. Singer, Y. Chang, M.C. Fang, and et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation Ann Intern Med 151 2009 297 305
6. J.B. Olesen, G.Y. Lip, J. Lindhardsen, and et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a "real world" nationwide cohort study Thromb Haemost 106 2011 739 749
7. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, et al. for the RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
8. M.R. Patel, K.W. Mahaffey, J. Garg, et al. for the ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
9. C.B. Granger, J.H. Alexander, J.J. McMurray, et al. for the ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
10. A. Banerjee, D.A. Lane, C. Torp-Pedersen, and G.Y. Lip Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a "real world" atrial fibrillation population: a modelling analysis based on a nationwide cohort study Thromb Haemost 107 2012 584 589
11. R.P. Giugliano, C.T. Ruff, E. Braunwald, et al. for the ENGAGE AF-TIMI 48 Investigators Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
12. F. Skjøth, T.B. Larsen, L.H. Rasmussen, and G.Y. Lip Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis Thromb Haemost 111 2014 981 988
13. P. Verdecchia, F. Angeli, G.Y. Lip, and G. Reboldi Edoxaban in the evolving scenario of non-vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons PLoS One 9 2014 e100478
14. R. Nieuwlaat, A. Capucci, A.J. Camm, et al. for the European Heart Survey Investigators Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation Eur Heart J 26 2005 2422 2434
15. R. Pisters, R. Nieuwlaat, D.A. Lane, H.J. Crijns, and G.Y. Lip Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey Thromb Haemost 109 2013 328 336
16. S. Shulman, C. Kearon Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694
17. Eurostat. Population on 1 January. Available at: http://ec.europa.eu/eurostat/tgm/table.do?tab=table&plugin=1&language=en&pcode=tps00001. Accessed November 29, 2015.
18. A.J. Camm, P. Kirchhof, G.Y. Lip, et al. for the ESC Committee for Practice Guidelines Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Europace 12 2010 1360 1420
19. T.P. Van Staa, E. Setakis, G.L. Di Tanna, D.A. Lane, and G.Y. Lip A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice J Thromb Haemost 9 2011 39 48
20. R. Romero-Ortuno, and D. O'Shea Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice Age Ageing 41 2012 250 254
21. L. Boulanger, J. Kim, M. Friedman, O. Hauch, T. Foster, and J. Menzin Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice Int J Clin Pract 60 2006 258 264
22. S. Monte, A. Macchia, F. Pellegrini, and et al. Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation Eur Heart J 27 2006 2217 2223
23. G.Y.H. Lip The role of aspirin for stroke prevention in atrial fibrillation Nat Rev Cardiol 8 2011 602 606
24. D.J. Graham, M.E. Reichman, M. Wernecke, and et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation Circulation 131 2015 157 164
25. N.S. Roskell, G.Y. Lip, H. Noack, A. Clemens, and J.M. Plumb Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate Thromb Haemost 104 2010 1106 1115
26. M. Hordijk-Trion, M. Lenzen, W. Wijns, et al. for the EHS-CR Investigators Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization Eur Heart J 27 2006 671 678
27. 2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation Am J Med 127 2014 1083 1088
28. A.M. Gallagher, E. Setakis, J.M. Plumb, A. Clemens, and T.P. van Staa Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients Thromb Haemost 106 2011 968 977
29. P.B. Nielsen, D.A. Lane, L.H. Rasmussen, G.Y. Lip, and T.B. Larsen Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis Clin Res Cardiol 104 2015 418 429